Yüklüyor......
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
The treatment for chronic myeloid leukemia has changed significantly over the past 15 years, and as of now, there are five BCR-ABL1 (breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1) tyrosine kinase inhibitors that have gained approval for treatment of this disease. All fiv...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4099191/ https://ncbi.nlm.nih.gov/pubmed/25045255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S53160 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|